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required to activate the MEKK Ste11 
Yuanyi Feng, Lin Ye Song, Eleanor Kincaid, Sanjoy K. Mahanty
and Elaine A. Elion
Background: In the budding yeast Saccharomyces cerevisiae, the pheromones
that induce haploid cells of opposite cell types to mate activate the Gβ and Gγ
subunits of a heterotrimeric G protein. These subunits signal through the PAK
kinase Ste20 to activate a mitogen-activated protein (MAP) kinase cascade
comprising the MEKK Ste11, the MEK Ste7 and two MAP kinases, Fus3 and
Kss1. The pathway requires Ste5, a scaffold protein that tethers the MAP
kinase cascade enzymes into a high molecular weight complex. Ste5 is thought
to associate with Gβ in a pheromone-independent manner, but it is not known if
this interaction affects signaling.
Results: A ste5C180A mutant — which expresses Ste5 disrupted in the LIM
domain, a putative metal-binding motif that has been proposed to be essential
for Ste5 oligomerization – could not transmit the pheromone signal from Gβ
through Ste20 to Ste11. The Ste5C180A protein was impaired in binding Gβ,
although it could oligomerize, bind Ste11, Ste7 and Fus3, facilitate the basal
activation of Ste11, and relay the Ste11 signal to MAP kinases. Ste5 bound to
Gβ in a pheromone-dependent manner and preferentially associated with a
phosphorylated form of Gβ in wild-type and ste20∆, but not in ste5C180A,
strains.
Conclusions: Pheromone induces binding of Gβ to Ste5 through its LIM
domain. This binding is essential for activation of Ste11 and is distinct from the
ability of Ste5 to oligomerize or to serve as a scaffold and relay the signal from
Ste11 to the MAP kinases. Pheromone also induces Ste5-dependent
phosphorylation of Gβ.
Background
Mating of haploid cells of the budding yeast Saccharomyces
cerevisiae is regulated by a mitogen-activated protein
(MAP) kinase cascade that is activated by the binding of
peptide pheromone to a serpentine receptor. The acti-
vated receptor causes an inhibitory Gα subunit to dissoci-
ate from a Gβ–Gγ dimer of a heterotrimeric G protein
[1,2]. The Gβ–Gγ subunits propagate the signal through
the PAK kinase Ste20 [3–5], possibly through a direct
interaction [6,7]. Ste20 is thought to activate the MAP
kinase (ERK) kinase kinase (MEKK) Ste11, on the basis
of epistasis tests that place Ste20 before Ste11 in the
pathway [3,4]. Phosphorylation of Ste11 by Ste20 in vitro
does not alter Ste11 activity [8], suggesting that other
proteins are required. Ste11 activates the MEK (MAP
kinase kinase) Ste7 [9], and Ste7 activates two function-
ally redundant MAP kinases, Fus3 and Kss1 [10]. These
MAP kinases promote many responses including gene
activation, cell cycle arrest in the G1 phase, morphogene-
sis, and cell fusion. These responses are thought to arise
by the direct phosphorylation of multiple targets by the
MAP kinases [11–15]. 
Activation of Ste11 by the Gβ subunit of the G protein
(encoded by the STE4 gene) requires two other proteins,
Ste50 and Ste5. Ste50 regulates Ste11 by an unknown
mechanism and is not essential for signal transduction [16].
Ste5 is essential for signaling and has multiple functions
[17]. Ste5 has been proposed to act as a scaffold that co-
localizes Ste11, Ste7 and Fus3/Kss1 [18–20]. Ste5 has sepa-
rable binding domains for each of the kinases that binds it
[19], and tethers them into a high molecular weight complex
[19] of high specific activity (J.A. Kranz, S.M. Mahanty and
E.A.E., unpublished observations). This complex may facil-
itate signal transmission from Ste11 to Fus3 as well as feed-
back phosphorylation of upstream components [17]. Ste5
also interacts with regulators of morphogenesis and G1
arrest and may localize the MAP kinase cascade to sub-
strates involved in these outputs [21,22]. Ste5 may directly
regulate Ste11; its overexpression is sufficient to activate
Ste11 in the absence of a signal [19] and it associates with
the regulatory domain of Ste11 [19,20] which is known to be
inhibitory [23]. A gain-of-function mutation located within
this regulatory domain (STE11-1) [24] increases the ability
of Ste11 to interact with Ste5 in a two-hybrid system [25]. 
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Ste5 associates with Gβ through its amino-terminal
214 amino acids [26], suggesting that a Gβ–Ste5 interac-
tion is required for signal transmission. Ste5 oligomerizes
through two regions [27], one of which may overlap a
bipartite metal-binding motif which resembles a LIM
domain [17]. While not identical to a LIM domain, for
simplicity we will refer to this motif as a LIM domain.
LIM domains mediate homodimeric and heterodimeric
interactions in many proteins including transcription
factors and cytoskeletal proteins implicated in signaling
[28]. Ste5 oligomerization has been proposed to be essen-
tial for signal transduction [27] and to require the LIM
domain [29]. The LIM domain of Ste5 (residues
177–229) partially overlaps residues 1–214, which have
been implicated in Gβ binding, raising the possibility
that Gβ binding might involve the LIM domain and
affect Ste5 oligomerization. 
Here, we report the analysis of a Ste5 point mutant which
shows that the functional binding of Gβ to Ste5 through
the putative LIM domain of Ste5 is required for
pheromone-dependent activation of the MEKK Ste11.
This function is distinct from the ability of Ste5 to
oligomerize or to serve as a scaffold. Additional results
suggest that the Ste5–Gβ interaction may be pheromone
dependent. Ste5 is preferentially associated with a phos-
phorylated form of Gβ whose accumulation is dependent
on pheromone, and the kinase that catalyzes this phospho-
rylation is dependent on Ste5. Phosphorylation of Gβ in
the presence of pheromone may be a molecular ‘tag’ for
the activated form of Gβ.
Results
The ste5C180A mutant behaves phenotypically like a ste5
null mutant
We generated a cysteine to alanine point mutation at
residue 180 of Ste5 (Ste5C180A); this residue is within the
first of the two predicted zinc fingers that comprise the
LIM domain as well as the first 214 amino acids of Ste5,
which associate with Gβ [30]. The ste5C180A mutant was
sterile in a qualitative patch mating assay, like a ste5∆ null
mutant (Figure 1a); ste5C180A was also completely defec-
tive in pheromone-induced responses such as transcrip-
tional activation, G1 arrest, and morphological changes. We
used a β-galactosidase reporter gene under the control of
the FUS1 promoter (FUS1–LACZ) as a reporter for
pathway activity in ste5C180A. In contrast to wild-type
cells, FUS1 expression was not induced at all by α factor in
the ste5C180A mutant and remained at the same low levels
as in the ste5∆ null strain (Table 1). The ste5C180A mutant
did not undergo G1 arrest, as shown by persistent growth
in the presence of α factor (Figure 1b) and the absence of
unbudded cells with projections (termed shmoos; data not
shown). This complete absence of function did not seem
to be due to destabilization of the protein as the abundance
of Ste5C180A was similar to that of Ste5 (Figure 1c). Thus,
cysteine 180 is essential for the activity of Ste5 with
respect to all aspects of signaling measured.
Ste5C180A is able to associate with Ste11, Ste7 and Fus3
To understand the nature of the signaling defect of
ste5C180A, we tried to pinpoint the block in signal trans-
duction. We first tested the ability of the mutant protein
to function as a scaffold for the kinases on the MAP kinase
pathway. Two-hybrid analysis showed that the Ste5C180A
protein was able to associate with Ste11, Ste7 and Fus3
(Table 2). Fus3 interacted nearly equally well with
Ste5C180A as it did with wild-type Ste5. Ste11 and Ste7
also interacted efficiently with Ste5C180A, but at some-
what lower levels than they did with wild-type Ste5. A
simple reduction in the level of interaction with Ste11 and
Ste7 cannot account for the complete block in signaling,
because overexpression of Ste5C180A (by introduction of
the ste5C180A gene on a two micron (2µ) plasmid) did not
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Figure 1
The ste5C180A mutant behaves like a ste5 null mutant. (a) Sterility of
ste5C180A in a patch mating assay. Strain EY1775 (ste5∆)
containing either the CEN URA3 plasmid alone (vector) or this plasmid
harboring either STE5 or ste5C180A was mated for 5 h at 30°C on
YPD (yeast extract peptone dextrose medium), before replica-plating to
a YNB (yeast nitrogen base medium) plate to select for diploids. 
(b) The ste5C180A mutant is α-factor resistant. The same strains as in
(a) were tested in halo assays using 3 µl 167 µM α factor. 
(c) Ste5C180A protein is as abundant as wild-type Ste5. Immunoblot
of extracts prepared from EY1775 strains containing CEN URA3
plasmids harboring genes encoding Ste5 or Ste5C180A tagged with
three copies of the Myc epitope (STE5–Myc3 and ste5C180A–Myc3).
Whole cell extracts (30 µg) were loaded in both lanes. The immunoblot
was probed with the anti-Myc monoclonal antibody 9E10.
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rescue the absence of function in a ste5 null mutant (data
not shown). Thus, the mutant protein is able to associate
with all three kinases — Ste11, Ste7 and Fus3 — suggest-
ing that its strong defect in signal transduction is at
another step of signal transmission. 
Ste5C180A is able to basally activate Ste11 and facilitate
signal transmission to the MAP kinases
If the Ste5C180A protein retains scaffolding functions,
then it should be able to positively regulate the basal
activity of Ste11 and allow signaling from Ste11 through
Ste7 to Fus3. We first tested this by determining whether
the ste5C180A mutant retains the ability to positively regu-
late a constitutively hyperactive allele of STE11, STE11-4,
in the absence of mating pheromone. The STE11-4 gene
encodes a protein with a single amino acid change in the
catalytic domain that significantly raises the basal activity
of Ste11 as quantitated by expression of the FUS1 gene
[24]. Full basal activity of STE11-4 requires a functional
Ste5 protein, because a ste5∆ STE11-4 strain has only 10%
of the level of FUS1 expression present in a STE5 
STE11-4 strain [24]. Mutations in either Gβ or the
pheromone receptor have no effect on constitutive activa-
tion of FUS1 by STE11-4, while mutations in either STE7
or FUS3 and KSS1 block activation [24]. Thus, the level of
basal FUS1 expression in a ste5C180A STE11-4 strain
provides a sensitive means to monitor whether the
Ste5C180A protein can positively regulate Ste11 and can
transmit its signal to the MAP kinases. Ste5C180A
enhanced the basal activity of the Ste11-4 protein, as
shown by three-fold higher levels of constitutive FUS1
expression (Table 1, – α factor column), and restored
mating in the ste5C180A STE11-4 strain compared with
the ste5∆ STE11-4 strain (Figure 2a). This result strongly
argues that Ste5C180A retains the ability to bind to and
positively regulate Ste11. 
Additional experiments using a fusion protein of gluta-
thione-S-transferase (GST) and Ste5C180A also argue
that the Ste5C180A protein facilitates Ste11 function.
For reasons that are not yet clear, the addition of GST to
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Table 1
The ste5C180A mutant does not respond to a factor but does
activate STE11-4 to a basal level.
β-galactosidase activity
(Miller units)
Strain Plasmid – α factor + α factor
ste5 ∆ STE5 CEN 0.46 ± 0.05 89.7 ± 13.0
ste5 ∆ ste5C180A CEN 0.22 ± 0.05 0.24 ± 0.03
ste5 ∆ CEN 0.24 ± 0.08 0.25 ± 0.08
STE11-4 ste5 ∆ STE5 2µ 203.9 ± 58.7 338.0 ± 59.5
STE11-4 ste5 ∆ ste5C180A 2µ 109.4 ± 29.5 117.6 ± 24.3
STE11-4 ste5 ∆ 2µ 35.9 ± 4.0 35.8 ± 4.0
STE11-4 ste20 ∆ 2µ 175.8 ± 7.7 375.2 ± 22.5
ste5 ∆ GAL1p–GST–STE5 2µ 2.84 ± 0.79 17.37 ± 4.50
ste5 ∆ GAL1p–GST–ste5C180A 2µ 0.56 ± 0.12 0.63 ± 0.24
ste5 ∆ GAL1p–GST 2µ 0.15 ± 0.08 0.14 ± 0.04
The response to α factor was assessed by measuring the
β-galactosidase activity in cells expressing a FUS1–LACZ reporter
gene. The ste5∆ strain (EY1775) contained FUS1–LACZ (pJB207)
and centromeric (CEN) plasmids either alone or harboring STE5
(pYBS138) or ste5C180A (pEK1). The STE11-4 strain (S74)
contained FUS1–LACZ (pJB207) and the two micron (2µ) plasmid
either alone or harboring STE5 (pSCEM20) or ste5C180A
(pSCEM22). STE11-4 ste20∆ strain EY1981 contained FUS1–LACZ
(pJB207) and YCplac195. Strains were grown to an A600 of ~0.4 at
30oC and induced by adding either 50nM α factor (+ α factor) or an
equal volume of 90% methanol (– α factor) for 90 min. For the
glutathione–S-transferase (GST) fusion proteins GST–Ste5 and
GST–Ste5C180A, the ste5∆ strain EY1775 containing FUS1–LACZ
(pSB231) and GST–STE5 (pYEE170), GST–ste5C180A (pLS29) or
GST (pYEE161) was pregrown in raffinose medium to an A600 of ~0.6.
Cells were pelleted, resuspended in galactose medium at an A600 of
~0.2, grown for 4 h and then induced as above. Extracts were
prepared and assayed for β-galactosidase activity as described in
Materials and methods. Results are shown as the mean ± the standard
deviation for four transformants. Strains expressing GST fusion
proteins had the CEN FUS1–LACZ plasmid while all other strains had
the 2µ FUS1–LACZ plasmid.
Figure 2
Ste5C180A basally activates Ste11. (a) The ste5C180A gene
enhances the ability of a STE11-4 ste5∆ strain to mate. A STE11-4
ste5∆ strain harboring STE5, ste5C180A, or vector alone (LEU2 2µ
plasmids), and a STE11-4 ste20∆ strain were tested for patch mating
as in Figure 1a. Cells were mated for 6 h at 30°C. The YNB plate was
photographed after ~48 h at 30°C. (b) The ste5C180A gene
enhances the ability of Ste11 and Ste7 to promote mating when
overexpressed. The ste5∆ strain EY1775 contained plasmids
encoding glutathione-S-transferase (GST) fusion proteins under the
control of the GAL1 promoter (GAL1p–GST, GAL1p–GST–Ste5 or
GAL1p–GST–ste5C180A) with or without GAL1p–STE11–Myc3 and
GAL1p–STE7–Myc3, which encode Myc-epitope-tagged Ste11 and
Ste7. Transformants were pregrown on SC (synthetic complete)
selective plates, then mated as in Figure 1 on a YEP plate with 2%
galactose for 6 h at 30°C. (c) A STE11-4 ste5C180A strain is blocked
for G1 arrest induced by α factor. The same strains as in (a), as well as
STE11-4 containing a LEU2 2µ vector (+ vector), were tested in a
halo assay.
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wild-type Ste5 greatly enhances the activity of Ste5 as
measured by mating and activation of Fus3 kinase [18].
GST–Ste5 is able to fully activate Fus3 and complement
the mating defect of a ste5 null mutant under conditions
in which GST–Ste5 is expressed at levels too low to
detect (when it is under the control of a repressed GAL1
promoter). This GST–Ste5 fusion is likely to be a gain-
of-function derivative of Ste5 because it constitutively
induces the expression of the FUS1–LACZ reporter gene
under the conditions of negligible expression (data not
shown). GST also enhanced the activity of Ste5C180A,
shown by an enhancement in the basal signaling from the
FUS1–LACZ reporter (Table 1). This enhanced basal
signaling was associated with a weak mating capacity
(Figure 2b). Strikingly, overexpression of either Ste11 or
Ste7 greatly enhanced the ability of the strain expressing
GST–Ste5C180A to mate, contrasting the absence of an
effect in the ste5∆ null strain (Figure 2b). Taken
together, the results argue compellingly that Ste5C180A
facilitates both Ste11 activation of Ste7 and Ste7 activa-
tion of the MAP kinases. This is consistent with the two-
hybrid results showing that Ste5C180A is able to function
as a scaffold.
The ste5C180A mutant is blocked at the Gb and Ste20
steps of pheromone-dependent activation of Ste11 
We determined whether Ste5C180A is defective in trans-
mitting an activating signal to Ste11 from an upstream
component. Gβ, Ste20 and Ste50 have been positioned
upstream of Ste5 and Ste11 and are thought to positively
regulate its activity. Overexpression of Gβ (encoded by
the STE4 gene), Ste20 and Ste50 stimulated signal trans-
duction in a wild-type strain, but did not bypass the signal
transduction defect of the ste5C180A mutant as assayed by
mating (Figure 3a), transcriptional activation of a HIS3
reporter gene driven by the FUS1 promoter (FUS1–HIS3;
Figure 3b, data shown for Gβ and Ste20 only), and G1
arrest (Figure 3c, data shown for Gβ only). This block in
signal transduction was very tight. Despite a high level of
basal activation of FUS1 in the ste5C180A STE11-4 double
mutant, this strain did not respond to α factor, as shown by
the absence of an increase in FUS1–LACZ expression
levels (Table 1, + α factor column) and the absence of G1
arrest (Figure 2c). The ability of this strain to mate
(Figure 2a) is therefore due to the high level of constitu-
tive functioning of the Ste11-4 protein, rather than to a
pheromone-dependent event. Overexpression of Gβ,
Ste20 or Ste50 did not increase the mating of the STE11-4
ste5C180A strain (Figure 3a), and overexpression of Gβ did
not increase the mating of the GST–Ste5C180A strain (data
not shown). The fact that excess Gβ, Ste20 and Ste50 had
no effect in the STE11-4 ste5C180A strain contrasts their
ability to enhance signaling in a STE11-4 STE5 strain (V.
Cherkasova, D.M. Lyons and E.A.E., unpublished obser-
vations). Thus, ste5C180A is tightly blocked for a
pheromone-dependent event that requires both Gβ and
Ste20 and occurs at or upstream of Ste11.
An intact Ste5 LIM domain is sufficient to bind to Gb and
blocks Gb-mediated signaling when overexpressed
We tested whether the LIM domain of Ste5 mediates the
interaction with Gβ, and whether the ste5C180A mutation
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Table 2
Ste5C180A is severely defective in its interaction with Gb but not with Ste11, Ste7, Fus3 or Ste5.
B42 B42–Ste5 B42–Ste5C180A
LexA–Ste11 0.5 ± 0.1 703 ± 129 296 ± 48
LexA–Ste7 9.34 ± 1.5 728 ± 106 288 ± 50
LexA–Fus3 1.27 ± 0.5 45.1 ± 9.1 37.0 ± 10.7
LexA–Gβ 33043 ± 5521 77711 ± 13690 24414 ± 3939
B42 B42–Gb
LexA–Ste5(1–176) 2.4 ± 0.3 2.7 ± 0.1
LexA–Ste5(1–214) 17.3 ± 5.0 232 ± 5.0
LexA–Ste5C180A(1–214) 1.2 ± 0.6 1.8 ± 0.3
LexA–Ste5(1–230) 147.5 ± 31 298.5 ± 18
LexA–Ste5C180A(1–230) 1.33 ± 0.1 1.45 ± 0.1
B42 B42–Ste5 B42–Ste5C180A
LexA–Ste5(1–214) 3.0 ± 0.4 457.3 ± 113 1164 ± 103
LexA–Ste5C180A(1–214) 0.4 ± 0.15 5.6 ± 5.3 27.0 ± 7.7
LexA–Ste5(1–336) 351 ± 103 1495 ± 473 1123 ± 194
LexA–Ste5C180A(1–336) 0.31 ± 0.04 2.8 ± 0.17 14.0 ± 7.6
Two-hybrid analysis was performed using LexA and B42 fused to
intact proteins or the regions encompassed by the amino acid residues
indicated. Most two-hybrid interactions were analyzed in strain AMR70.
LexA–Gβ was assayed in a ste11∆ fus3∆ strain (EY1453) with the
LexAop–LACZ LEU2 two micron (2µ) plasmid (pYEE158) to avoid
constitutive pathway activation by ADHpLexA–Ste4. 
Ste5 oligomerization was assayed in an a/α diploid (from a cross
between AMR70 and EY698 [11]). Cells were grown and lysates
prepared and assayed for β-galactosidase activity as described in
Materials and methods. The results are shown as the mean ± the
standard deviation and are the average from four transformants.
abolishes this interaction. As shown by two-hybrid analysis,
a B42–Ste5C180A fusion protein did not interact at all with
a LexA–Gβ fusion protein, in contrast to an obvious ability
of B42–Ste5 to interact with LexA–Gβ (Table 2), suggest-
ing that Ste5C180A is defective in binding to Gβ. Co-
immunoprecipitation experiments recapitulated these
two-hybrid results. A Myc-epitope-tagged fragment (amino
acids 1–242) of Ste5, Ste5(1–242), co-purified with a func-
tional hemagglutinin (HA)-epitope-tagged Gβ from yeast
whole cell extracts, while the same fragment harboring the
C180A mutation was defective (Figure 4a). Taken together
the data strongly argue that the LIM domain mediates the
interaction between Ste5 and Gβ, and provide a possible
explanation for the null phenotype of ste5C180A.
Two-hybrid tests of three amino-terminal Ste5 fragments
that span the LIM domain show that an intact LIM
domain is essential for binding to Gβ (Table 2). A
LexA–Ste5(1–176) fusion, which lacks the LIM domain,
did not interact with a B42–Gβ fusion. By contrast,
LexA–Ste5(1–214) and LexA–Ste5(1–230) fusions, which
span the LIM domain, interacted with B42–Gβ. While
this analysis is complicated by the fact that the
LexA–Ste5(1–230) fusion activated transcription at the
LexA operator in the absence of an interaction, it is clear
that more interaction was detected with B42–Gβ than
with B42. The introduction of the C180A mutation into
LexA–Ste5(1–214) and LexA–Ste5(1–230) abolished their
ability to interact with B42–Gβ. This absence of an inter-
action is unlikely to be due to a gross conformational
change, because both LexA–Ste5C180A(1–214) and
LexA–Ste5C180A(1–336) efficiently interacted with
B42–Ste5 (Table 2).
We tested whether an interaction between the Ste5 frag-
ments and Gβ correlated with function, by determining
whether the fragments would interfere with Gβ-mediated
signaling when overexpressed. As shown in Figure 5, the
two-hybrid results predicted whether or not the amino-
terminal fragments inhibited Gβ-mediated signaling.
Ste5(1–176), which did not interact with Gβ, had no
effect on α-factor-induced G1 arrest. By contrast, both
Ste5 fragments that overlap the LIM domain efficiently
blocked G1 arrest in wild-type cells and STE11-4 cells,
with better inhibition by the fragment with a complete
LIM domain. Moreover, neither of the C180A derivatives
of these fragments blocked signaling. Thus, the LIM
domain is necessary and sufficient to inhibit Gβ-mediated
signaling when overexpressed, and this inhibition corre-
lates with binding to Gβ.
Overexpression of a LIM domain blocks Ste20-independent
signal transmission
Previous work suggests that Gβ activates Ste11 by two
mechanisms, one that is dependent upon Ste20 catalytic
activity, and one that is distinct. First, a ste20∆ deletion
strain is not fully sterile [6]. Second, a STE11-4 ste20
double mutant undergoes pheromone-induced G1 arrest
and enhancement in Fus3 activity (Figure 2c) [21] and
FUS1 expression (Table 1). This bypass does not occur in
STE11-4 ste4∆ or STE11-4 ste5∆ double mutants [21],
arguing that Gβ mediates signal transduction through
Ste20 and a less essential auxiliary pathway of signaling
that requires Ste5 [21]. The LIM domain seems to be
required for this auxiliary pathway of signaling for two
reasons; first, STE11-4 did not bypass the pheromone-
dependent block of a ste5C180A mutant, although it did
bypass the ste20∆ mutant (Table 1, Figure 2c). Second,
overexpression of the set of Ste5 fragments that block G1
arrest in a wild-type strain also block G1 arrest in a 
STE11-4 ste20∆ strain (Figure 5). Thus, the LIM domain
is required for this parallel pathway of signaling that oper-
ates in the absence of Ste20. 
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Figure 3
Overexpression of Gβ, Ste20 and Ste50 does not suppress
ste5C180A. (a) Overexpression of Gβ, Ste20 and Ste5 does not
restore mating to ste5C180A. The ste5∆ strain (EY1775) containing
CEN URA3 STE5 (pYBS138), CEN URA3 ste5C180A (pEK1) or
vector alone was transformed with GAL1p–STE4 (pYEE116),
GAL1p–STE20 (ZM44STE20), or GAL1p–STE50 (ZM44STE50),
respectively. Transformants were tested for patch mating on YEP plates
containing 2% galactose as described in Figure 1a. (b) GAL1p–STE4
and GAL1p–STE20 do not restore FUS1 expression to ste5C180A. A
ste5∆ far1∆ his3 ∆200 strain with FUS1–HIS3 integrated at the LYS2
locus (EY2019) was co-transformed with CEN plasmids harboring
STE5 (pYBS138), ste5C180A (pEK1) or vector control and either
GAL1p–STE4 (pL19) or GAL1p–STE20 (ZM44STE20).
GAL1p–STE4 transformants were tested for growth on SC selective
plates containing galactose and lacking histidine. GAL1p–STE20
transformants were tested in the same way, except that the plate also
contained enough α factor to stimulate expression of FUS1–HIS3, but
not G1 arrest, in the presence of STE5. (c) GAL1p–STE4 does not
induce growth arrest in ste5C180A. The transformants described in (a)
were streaked on SC selective plates containing 2% dextrose (Dex) or
2% galactose (Gal) and incubated at 30°C.
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Ste5C180A is defective in binding to Gb
To detect a possible physiological defect in binding
between Gβ and Ste5C180A in vivo, we first characterized
the interaction between wild-type Ste5 and Gβ using
functional tagged versions of Ste5 and Gβ (Ste5–Myc9
and HA–Gβ). HA–Gβ was expressed from the GAL1 pro-
moter for various lengths of times, with or without subse-
quent repression of the promoter (Figure 4b), and
Ste5–Myc9 was expressed from its own promoter on a low-
copy centromere plasmid or on a high-copy 2µ plasmid.
Reasonable levels of specific binding between HA–Gβ
and Ste5–Myc9 were detected when Ste5–Myc9 was
maintained on a high-copy plasmid, and HA–Gβ was
expressed at low (Figure 4c) to high (Figure 4d) levels.
Specific binding was shown by the absence of HA–Gβ in
9E10 immunoprecipitates prepared from cells either
lacking Ste5–Myc9 or HA–Gβ. More binding was
detected when greater levels of HA–Gβ were expressed.
Similar results were found when HA–Gβ was immunopre-
cipitated (data not shown). When HA–Gβ was expressed
for 2 or more hours, HA–Gβ and Ste5–Myc9 associated in
the absence of pheromone (Figure 4c, lane 7; Figure 4d,
lane 1) and the association was not significantly altered by
α factor (data not shown). When HA–Gβ was expressed at
the lowest levels tested (Figure 4c, lanes 1,2), however,
Ste5–Myc9 preferentially bound to a form of Gβ that is
induced by α factor. Thus, the interaction between Ste5
and Gβ may be pheromone dependent.
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Figure 4
Analysis of the interaction between Gβ and Ste5 in whole cell extracts.
(a) Ste5(1–242) harboring the C180A mutation is defective in
associating with Gβ. Wild-type (EY1118) strains containing plasmids
encoding Myc-epitope-tagged fragments of Ste5 —
STE5(1–242)–Myc9 (pLS47) or ste5C180A(1–242)–Myc9 (pLS48)
— and HA-epitope-tagged Gβ — GAL1p–HA–Ste4 (pYEE181) — were
grown and extracts were prepared as described in Materials and
methods. Ste5(1–242)–Myc9 and Ste5C180A(1–242)–Myc9 were
immunoprecipitated (9E10 IP) from 5 mg whole cell protein extract
(WCE) using 9E10. Immune complexes were subjected to
SDS–PAGE and immunoblotted with rabbit anti-HA antibody to detect
HA–Gβ or anti-Myc 9E10 antibody to detect Ste5(1–242)–Myc9 and
Ste5C180A(1–242)–Myc9. (b) Relative levels of HA–Gβ in
immunoprecipitation experiments. Immunoblot analysis of 20 µg whole
cell extract from strains expressing HA–Gβ for different lengths of time
by inducing with galactose (Gal) for 0.5, 1, 2, 4 and 7 h, and
repressing with dextrose (Dex) for 1 h where indicated. The asterisk (*)
indicates a cross-reacting protein that is apparent when HA–Gβ levels
are low. (c) Ste5C180A–Myc9 is defective in binding to HA–Gβ.
Immunoprecipitations were performed as in (a) using the ste4∆ ste5∆
strain (S36) with STE5–Myc9 (pLS42) or ste5C180A–Myc9 (pLS43)
and GAL1p–HA–STE4 (pYEE181). Negative controls were ste5∆
ste4∆ strains harboring control vector with HA–Gβ and control vector
with Ste5–Myc9. Cells were grown in galactose medium for 2 h to
express HA–Gβ, then either harvested directly (lanes 7–10), or
pelleted and resuspended in 2% dextrose containing medium for an
additional hour to repress the expression of HA–Gβ (lanes 1–6). The
indicated samples had 50 nM α factor added for 10 min (lanes 2,4).
(d) Ste5C180A–Myc9 and Ste5∆LIM–Myc9 associate with HA–Gβ
when HA–Gβ is overexpressed. The ste4∆ ste5∆ strain (S36)
containing STE5–Myc9 (pLS42), ste5C180A–Myc9 (pLS43), or
ste5∆LIM–Myc9 (pLS46) and GAL1p–HA–STE4 (pYEE181) was
grown in galactose medium for 4 h before preparing extracts. Samples
were immunoprecipitated as in (a). (e) Ste5–Myc9 is preferentially
associated with phosphorylated HA–Gβ. The ste5∆ ste4∆ (S36)
ste20∆ (EY1463) and bem1∆ (EY2372) strains containing
STE5–Myc9 (pLS40) and GAL1p–HA–STE4 (pYEE181) were grown
in SC selective medium containing galactose for the indicated amount
of time and Ste5–Myc9 was immunoprecipitated as described in (c). 
Significantly lower levels of HA–Gβ co-precipitated with
Ste5C180A–Myc9 than with Ste5–Myc9 when HA–Gβ
was expressed for 2 hours (Figure 4c, lane 8). The reduc-
tion of HA–Gβ in the Ste5C180A–Myc9 immunoprecipi-
tates was due to a loss of binding capacity, because
equivalent levels of Ste5–Myc9 and Ste5C180A–Myc9
were present in the whole cell extracts. Even more dra-
matically, no binding was detected for Ste5C180A–Myc9
(or Ste5∆LIM–Myc9, which has residues 177–229 of the
LIM domain deleted; data not shown) when HA–Gβ was
expressed at lower levels (Figure 4c, lanes 3,4). Thus, sig-
naling by Gβ to Ste11 correlated with the ability of Gβ to
bind to Ste5 through the LIM domain.
Forced binding between Gb and Ste5C180A does not
suppress the signaling block
It was possible to detect an association between HA–Gβ
and either Ste5C180A–Myc9 or Ste5∆LIM–Myc9 when
HA–Gβ was expressed at high enough levels. Residual
binding between Ste5C180A–Myc9 and HA–Gβ was
detected when HA–Gβ was expressed for 2 hours
(Figure 4c, lane 8). Significant amounts of binding were
detected for both Ste5C180A and Ste5∆LIM when
HA–Gβ was expressed for 4 hours (Figure 4d, lanes
2,5,6), indicating that binding is independent of the LIM
domain. Equivalent binding between HA–Gβ and
Ste5–Myc9 occurred in ste20∆ and bem1∆ strains
(Figure 4e, similar results were found for Ste5C180A),
suggesting that Ste20 and Bem1 do not mediate this
interaction. Because this interaction does not involve the
LIM domain and is revealed under conditions in which
HA–Gβ and Ste5–Myc9 are overexpressed, it may not be
physiologically relevant. Importantly, signal transduction
was still blocked in these strains. Thus, while Gβ and
Ste5 may associate through additional direct or indirect
interactions, this association cannot substitute for the
critical role of the LIM domain in signaling.
Ste5 binds preferentially to a form of Gb that has been
hyperphosphorylated by a Ste5-dependent kinase
Our analysis revealed that Ste5 was preferentially associ-
ated with a hyperphosphorylated form of Gβ that arises
in the presence of α factor or when Gβ is overexpressed.
Previous work has demonstrated that Gβ is rapidly phos-
phorylated in the presence of α factor [31]. Gβ phospho-
rylation was demonstrated by the accumulation of slower
migrating species (Figure 4b–e) that disappeared upon
treatment with phosphatase (data not shown). The phos-
phorylated species accumulated when cells were treated
with α factor or when Gβ was overexpressed and consti-
tutively activated the pathway (Figure 4c–e; activation
monitored by FUS1–LACZ, data not shown). That Ste5
preferentially associated with the phosphorylated form of
Gβ was most dramatically shown under conditions in
which Gβ was expressed at low levels. The Ste5–Myc9
immunoprecipitates only contained the phosphorylated
form of Gβ, despite the fact that it was not readily
detected in the whole cell extracts (Figure 4c; similar
results were found for α-factor induction times of 10, 20
and 30 minutes). Under conditions in which Gβ was
expressed at higher levels, Ste5–Myc9 immunoprecipi-
tates were always enriched for the phosphorylated form
(Figure 4d,e).
Gβ was not phosphorylated in the ste5C180A mutant, as
shown by the absence of slower migrating species in
pheromone-treated cells or in cells that had high levels
of Gβ. Therefore, Gβ is phosphorylated by a protein
kinase whose activity requires Ste5, suggesting that the
kinase acts downstream of Ste5 in the pathway. Consis-
tent with this, Gβ was still phosphorylated at low levels
in ste20∆ and bem1∆ mutants, which have reduced levels
of signal transduction due to blocks upstream of Ste11
(Figure 4e). 
Ste5C180A oligomerizes more efficiently than wild-type
Ste5 
The inability of Gβ to interact with Ste5C180A could be
an indirect consequence of a defect in oligomerization. We
addressed this issue in a series of experiments that directly
measure oligomerization. As shown by two-hybrid analysis
(Table 2), LexA–Ste5(1–214) and LexA–Ste5(1–336)
fusion proteins oligomerized with B42–Ste5 in diploid
strains that did not express the endogenous STE5 gene.
Thus, sequences sufficient for oligomerization of these
fragments lie within the first 214 residues of Ste5.
LexA–Ste5(1–214) and LexA–Ste5(1–336) each interacted
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Figure 5
A functional LIM domain blocks G1 arrest when overexpressed. Amino-
terminal fragments of Ste5 and Ste5C180A containing the indicated
amino acids were expressed from the GAL1 promoter in wild-type
(WT; EY1118), STE11-4 (EY1298) and STE11-4 ste20∆ (EY2022)
strains. Halo assays were done in SC selective medium with 2%
galactose and 3 µl 167 µM α factor.
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with B42–Ste5C180A and LexA–Ste5C180A(1–214);
LexA–Ste5C180A(1–336) interacted with both B42–Ste5
and B42–Ste5C180A. Thus, oligomerization within the
first 214 amino acids of Ste5 may involve additional
residues. A comparison of the relative amount of interac-
tion suggests that Ste5C180A may oligomerize more
efficiently than wild-type Ste5.
We tested the ability of Ste5–Myc9 and Ste5C180A–Myc9
to co-purify with GST–Ste5 and GST–Ste5C180A.
GST–Ste5 associated with Ste5–Myc9 in a manner that
was unaffected by α-factor addition (Figure 6a).
Ste5C180A–Myc9 oligomerized efficiently with
GST–Ste5 (Figure 6b). Furthermore, GST–Ste5C180A
accumulated more oligomers than did GST–Ste5 as shown
by the relative amounts of wild-type and mutant Myc-
epitope tagged proteins that co-purified with each one
(Figure 6b). The increased amount detected in the pres-
ence of the C180A mutation was not due to variations in
the levels of the GST-tagged or Myc-tagged proteins in
the cells, on the basis of immunoblots of whole cell
extracts (data not shown). These findings agree with the
two-hybrid results. They also fit with the observation that
Ste5C180A had only a weak dominant-negative effect
when overexpressed (data not shown), despite the fact
that this protein binds the MAP kinase cascade enzymes.
Furthermore, a GST–Ste5∆143–313 mutant, which com-
pletely lacks the LIM domain [19], still oligomerized effi-
ciently with both Ste5–Myc9 and Ste5C180A–Myc9
(Figure 6c). This demonstrates that the LIM domain is
not required for oligomerization. Thus, we conclude that
the defect in binding between Gβ and Ste5C180A is
not due to a block in the ability of Ste5C180A to oligomer-
ize. The LIM domain may in fact negatively regulate
Ste5 oligomerization. 
Discussion
Binding of Ste5 to Gb through the LIM domain is essential
for pheromone-dependent activation of Ste11 by Ste20
Taken together, our data argue that an interaction
between Ste5 and Gβ through the putative LIM domain
of Ste5 is specifically required for transmission of the
pheromone signal from Gβ to Ste11. First, a point muta-
tion within this domain (ste5C180A) causes a strong defect
in the ability of Ste5 to associate with Gβ in vivo, although
it does not abolish the ability of Ste5 to associate with
Ste11, Ste7 and Fus3, or to oligomerize. Thus, in terms of
all known physical interactions for Ste5, Ste5C180A is
most severely defective in binding to Gβ. Second, the
defect in binding to Gβ correlates with a complete block
in pheromone-dependent signal transmission at the Gβ
step of the pathway, even when the basal activity of Ste11
is high due to the STE11-4 mutation. By contrast,
Ste5C180A is still able to facilitate signaling from Ste11 to
Ste7 and the MAP kinases, which is consistent with its
ability to bind to these enzymes. These data provide com-
pelling evidence that Ste5 has two distinct functions, one
required for pheromone-dependent activation of Ste11
through an interaction with Gβ, and a second required for
signal relay from Ste11 to the MAP kinases that may occur
through tethering the kinases.
Additional evidence argues that the putative LIM domain
of Ste5 is responsible for all of the binding to Gβ that is
required for signal transduction. First, a block in
pheromone signaling and a defect in the Ste5–Gβ interac-
tion that are similarly severe occur with a ste5∆LIM
mutation, which deletes the LIM domain (data not
shown). Second, two-hybrid analysis of Ste5 fragments
overlapping the LIM domain shows that the LIM domain
is necessary and sufficient to mediate the interaction with
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Ste5C180A oligomerizes more efficiently than wild-type Ste5. 
(a) Oligomerization between GST–Ste5 and Ste5–Myc9 is
independent of α factor. A ste5∆ strain (EY1775) with
GAL1p–GST–STE5 (pYEE170) and STE5–Myc9 (pSCEM21) was
grown for 5 hs in galactose medium to induce the expression of
GST–Ste5; 50 nM α factor was added for the indicated times.
GST–Ste5 was purified from whole cell extracts with glutathione
agarose as described in Materials and methods. 
(b) Ste5C180A–Myc9 forms more oligomers than Ste5–Myc9.
Samples were prepared as in (a) using a ste5∆ strain co-transformed
with plasmids harboring GST-tagged and Myc-tagged forms of Ste5
(pYEE170, pLS29, pSCEM1, pSCEM22). A plasmid encoding GST
was present in cells not expressing either one of the GST fusion
proteins. (c) Deletion of the LIM domain does not block
oligomerization. The same experiment was performed as in (b) except
that oligomerization by GST–Ste5 was compared with oligomerization
by GST–Ste5∆143–313 (encoded on pYEE166), which has the LIM
domain deleted.
Gβ. Third, the ability of Ste5 amino-terminal fragments to
interfere with Gβ-mediated signaling requires the pres-
ence of an intact LIM domain. While it is possible that
auxiliary interactions may occur between Gβ and Ste5, as
revealed under conditions in which both Gβ and
Ste5C180A are overexpressed, these interactions are not
sufficient to allow any signal transduction. We conclude
that a functional binding event between the putative Ste5
LIM domain and Gβ is critical for the activation of Ste11
by mating pheromone.
Ste5 may have a localization function that allows Ste11 to
be activated by Ste20
Our findings fit with a model in which the LIM domain of
Ste5 functions to localize Ste11 to the plasma membrane
where it can be activated by Ste20 in the presence of
mating pheromone. Ste20 is known to localize beneath the
plasma membrane through association with Cdc42 [8,9]
and is required for Ste11 function in vivo [5,6]. Although
Ste5C180A binds to Ste11, Ste7 and Fus3 and basally acti-
vates Ste11, its block in activation of Ste11 is not bypassed
by the overexpression of Ste20, even when the basal activ-
ity of Ste11 is enhanced by mutation. The simplest inter-
pretation of these results is that the association between
Gβ and Ste5 is required for Ste20 to activate Ste11. This is
consistent with the known requirement of Ste5 for Ste11
function [19,24,25], the physical interaction between the
two proteins [19,20,25], and the finding that Ste5–Myc9
and a fusion between Ste5 and green fluorescent protein
concentrate beneath the plasma membrane at the shmoo
tip in cells that have been treated with α factor (S.K.M.,
L.Y.S. and E.A.E., unpublished observations). 
Our results also suggest that Ste5 mediates activation of
Ste11 through another function that is distinct from
simple binding to Gβ. Ste20 is unable to activate Ste11 in
strains that overexpress both Gβ and Ste5C180A, despite
an association between these two proteins. One interpre-
tation of these results is that, in addition to binding to Gβ,
Ste5 must undergo a specific conformational change or
physically mediate a functional interaction between Ste11
and Ste20 that is required for the activation event. 
The Ste5 LIM domain also mediates a Ste20-independent
signaling event 
We extend previous work suggesting that Gβ mediates a
second signal distinct from activation of Ste20 that is
required to activate Ste11 [21]. Gβ is still phosphorylated
in a manner dependent on α factor and Ste5 in a ste20
deletion strain, demonstrating a specific signaling event at
the Gβ step that requires Ste5 but not Ste20. The fact that
a ste5C180A mutant is more defective in signaling than a
ste20∆ mutant, and overexpression of an intact LIM
domain blocks signaling in a ste20∆ STE11-4 strain,
provides strong evidence that the LIM domain of Ste5 is
required for this auxiliary signaling event. What mediates
this parallel pathway of activation? One possibility is that
Ste5 positively regulates Ste11 through allosteric interac-
tions. Ste11 may dimerize [19,25], suggesting one level of
regulation distinct from phosphorylation that could be
influenced by Ste5. It is conceivable that Ste11 activity is
enhanced by Ste5 oligomerization, as has been shown to
be the case for Raf-1 [32,33]. In addition, other proteins
may function with Ste20 to regulate Ste11, including
Ste50 [16], Ste21 [34], or a kinase with a functional overlap
with Ste20. 
Binding of Gb to Ste5 is not essential for oligomerization
Previous work suggests that oligomerization of Ste5 is
required for signal transduction [27]. We demonstrate here
that the LIM domain is not required for oligomerization of
Ste5. On the basis of two-hybrid analysis, oligomerization
requires amino acids within the first 176 residues of Ste5
that lie to the amino-terminal side of the LIM domain.
The fact that both Ste5C180A and a Ste5∆143−313
mutant, which is deleted for the LIM domain, oligomerize
efficiently argues compellingly that oligomerization is
required for another step in signal transduction. Several
lines of evidence suggest that oligomerization may stimu-
late basal signal transduction from Ste11 to the MAP
kinases. First, α factor has no effect on the amount of
oligomers detected for either wild-type Ste5 or
Ste5C180A, in contrast to its effect on binding of Ste5 to
Gβ. Second, fusion of a protein that dimerizes (GST) to
Ste5 increases basal signaling, but does not enhance the
response to α factor. Third, fusion of GST to Ste5C180A
stimulates the basal signaling capacity of this protein, but
does not suppress the block in α-factor-dependent signal-
ing. Ste5C180A oligomerizes somewhat more efficiently
than wild-type Ste5, suggesting that the LIM domain may
inhibit oligomerization. Such negative regulation might
prevent inappropriate activation of the MAP kinase
cascade in the absence of stimulus. Binding of Gβ to Ste5
may relieve this negative regulation, and at the same time
activate Ste5. 
Our conclusions disagree in part with those of Inouye et al.
[29], who analyzed a similar ste5 mutant, ste5177A180A, with
two mutations in the LIM domain. Inouye et al. [29] con-
clude, as we do, that residues within the LIM domain are
essential for binding to Gβ. However, these workers also
conclude that the LIM domain is required for oligomeriza-
tion, and propose that Gβ binding mediates Ste5 oligomer-
ization. Inouye et al. [29] argue that Ste5177A180A does not
oligomerize on the basis of interallelic complementation
tests. While it is possible that these indirect genetic tests
are not reliable, they may reflect a true defect in oligomer-
ization. If so, then we would have to conclude that the
double mutation causes additional conformational changes
that affect oligomerization, perhaps involving residues that
are amino terminal to the LIM domain and closest to the
Cys177→Ala mutation. Nevertheless, the fact that we find
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that both Ste5C180A and Ste5∆143–313, which lacks the
LIM domain (and cysteine 177), still oligomerize in a direct
biochemical test demonstrates that Gβ binding is not
required for oligomerization.
Inouye et al. [29] claim further support for their model with
the finding that fusion of GST to Ste5177A180A restores
mating to a Gβ mutant. However, we find that GST may
create a Ste5 ‘hypermorph’ that increases basal signaling
and simply bypasses Gβ function. While it is possible that
GST enhances the activity of Ste5 through its own ability
to dimerize [29], further work is required to determine
whether Gβ regulates the assembly of Ste5 oligomers. 
Understanding the role of oligomerization in signaling is
likely to be complex, as proper regulation of both associa-
tion and dissociation of Ste5 oligomers may be critical for
signal transduction. Preliminary analysis of a hyperactive
STE5HYP2 (ste5T52M [35]) mutant suggests that this gain-
of-function is due to reduced levels of oligomers, rather
than enhanced binding to Gβ, Ste11, Ste7, or Fus3 (Y.F.,
B. Satterberg and E.A.E., unpublished observations). In
addition, overexpression of GST–Ste5, which may accu-
mulate more oligomers than normal, blocks G1 arrest and
reduces maximal levels of FUS1 activation in a wild-type
strain (Y.F. and E.A.E., unpublished observations). Thus,
Ste5 complex formation may be a transient event, and
mutations that affect either complex assembly or disas-
sembly may have related phenotypes.
Ste5 may bind with highest affinity to free Gb
We demonstrate that under conditions in which Gβ is not
overexpressed, Ste5 binds to a form of Gβ that only exists
in the presence of α factor. This finding strongly suggests
that the interaction between Gβ and Ste5 is a
pheromone-dependent event and that Ste5 binds prefer-
entially to free Gβ that has been liberated from inhibition
by Gα. Previous work has suggested that the interaction
between Gβ and Ste5 is pheromone independent [26,29].
Gβ was overexpressed in these studies, however, creating
conditions that may have masked the pheromone depen-
dence. Our findings are consistent with the fact that the
LIM domain that mediates the binding between Ste5
and Gβ is required for pheromone-dependent activation
of Ste11.
We find that Ste5 preferentially associates with the hyper-
phosphorylated form of Gβ. One could argue that the
absence of binding between Gβ and Ste5C180A is an indi-
rect consequence of the block in phosphorylation of Gβ.
This is highly unlikely, however, as Gβ phosphorylation is
not required for signal transduction [31], and is mediated
by a kinase that acts downstream of Ste5 and requires the
Gβ–Ste5 signal for activity (Figure 4). Thus, Ste5 most
probably binds to free Gβ that has not been phosphory-
lated, consistent with the ability of Ste5 to interact with
Gβ in a two-hybrid assay in a ste11∆ mutant that lacks
pathway activity (Table 2). 
Phosphorylation of Gβ is believed to attenuate signal
transduction [31]. Fus3 attenuates signal transduction [1]
and phosphorylates other upstream signaling components
[18,19,36], raising the possibility that it is the Gβ kinase.
This is consistent with the fact that Fus3 is cytoplasmic
(K-Y. Choi, J.A. Kranz, S.M. Mahanty and E.A.E., unpub-
lished observations), requires Ste5 for kinase activity [18],
and binds to a region of Ste5 that is next to the LIM
domain [19], near the Ste5–Gβ binding interface. A cou-
pling between Gβ–Ste5 binding and Fus3 phosphoryla-
tion would provide a way to tightly regulate signaling at an
early rate-limiting step in the pathway.
Materials and methods
Strains and plasmids
A table showing the yeast strains used in this study is available as Sup-
plementary material (published with this paper on the internet). All inte-
grations were confirmed by Southern analysis. The functional
Ste5–Myc9 has 9 tandem c-Myc monoclonal 9E10 epitopes before
the Ste5 stop codon (S.K.M., L.Y.S., F. Farley and E.A.E., unpublished).
Plasmids pKC20 (Ste5–Myc3 URA3 2µ), pYEE170
(pGAL1–GST–STE5 LEU2 2µ), pYEE166 (pGAL1–GST–ste5∆5
LEU2 2µ), pYBS138 (STE5 URA3 CEN), pL19 (pGAL1–STE4 URA3
2µ) pYEE116 (pGAL1–STE4 HIS3 CEN), pKCS5 (pGAL1–STE7M
HIS3 CEN) and pKC11 (pGAL1–STE11M ADE2 CEN) are described
elsewhere [13,18,19,21,37]. Descriptions of all other plasmids are
available as Supplementary material (published with this paper on the
internet). 
Pheromone response assays
We measured α-factor sensitivity by halo assay as described [38],
using 50 µl overnight culture of yeast cells. The α-factor peptide (syn-
thesized by C. Dahl, Harvard Medical school), was dissolved in 90%
methanol and stored at –20°C. All halo assays were done at least in
duplicate, using 3µl 167 µM synthetic α factor. Qualitative patch
mating assays were done as described for 4–6 h at 30°C [38] using
YEP plates containing dextrose or galactose depending on the strains
tested. FUS1 transcription was assayed using a FUS1–LACZ fusion
(pJB207). Cells were grown to an A600 of 0.4, then they were induced
by 50 nM α factor for 90 min. Extracts were prepared and β-galactosi-
dase activity was measured as described [13].
Two-hybrid analysis
Plasmids encoding B42 and LexA fusion proteins were co-transformed
into strain AMR70. Four independent transformants were pregrown in
selective SC media containing 2% raffinose to an A600 of 0.8 to 1.2,
then cells were diluted to an A600 of 0.25 in selective media containing
2% galactose, grown for an additional 5 h, harvested, and extracts pre-
pared and assayed for β-galactosidase activity as described [19];
30–50 µg protein was typically assayed.
Co-immunoprecipitations
Strains containing genes under the control of the GAL1 promoter were
pregrown in selective SC media with 2% raffinose to an A600 of
1.0–1.3. Cells were pelleted and resuspended in selective SC media
containing 2% galactose at an A600 of 0.3 to 1.0, then further grown for
1–7 h and harvested either at an A600 of ~1.2 or grown for an addi-
tional hour in selective SC media containing 2% dextrose. Where indi-
cated, 50nM α factor was added 10–20 min before the cells were
collected. After being washed once with ice-chilled deionized water,
cells were frozen on dry ice and stored at –80°C for protein extraction.
Whole cell extracts were made as described [14], with an additional
276 Current Biology, Vol 8 No 5
back-extraction in precipitation buffer [26] containing 2 mM PMSF,
5 µg/ml each of pepstatin A, leupeptin, chymostatin and antipain.
Protein concentration was determined with Bio-Rad protein assay (Bio-
Rad). Whole cell protein (5–10 mg) was used to detect the interac-
tions between Ste5–Myc9 and HA–Gβ by co-immunoprecipitating in
1 ml precipitation buffer with 3 µg monoclonal antibody 9E10, or a
1:400 dilution of polyclonal rabbit anti-HA antibody (BAbCO) on ice for
1.5–2 h. Immune complexes were collected by incubating with 20 µg
Protein-A–sepharose (Phamacia Biotech) at 4°C for 1 h, then washed
five times with binding buffer. Samples were resuspended in
SDS–PAGE sample buffer and analyzed by immunoblotting. Extracts
used for detecting dimerization of Ste5–Myc9 and GST–Ste5 were
made similarly, using modified H buffer [14] containing 0.07% Triton-X
100 and 100 mM NaCl. For glutathione resin binding experiments,
250 µg protein was used. Binding of GST–Ste5 to glutathione agarose
was performed at 4°C for 3 h and complexes were washed three times
with modified H buffer containing 150 mM NaCl and once with the
same buffer containing 500 mM NaCl. Immunoblotting was performed
[14,18] with the ECL system (Amersham).
Supplementary material
Details of how the plasmids described in this study were generated
and tables showing the yeast strains and plasmids used are published
with this paper on the internet.
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Materials and methods
Plasmids
The ste5C180A gene was created by in vivo site-directed mutagene-
sis [S1]. A PCR product was made using 5′ primer CCTTTTTGAATG-
CTTCTTGTACGCTATCTGACGAGCCTATTTCTA, and 3′ primer
GGAAAGCGGGACTGAGGTGT. This PCR product, which overlaps
the MscI site, and contains the C180A mutation and a novel NheI site,
was co-transformed into a ste5∆ strain (EY1775) with linearized
plasmid pYBS138. NheI was used to diagnose incorporation of the
desired mutation. A ste5C180A-containing plasmid (pEK1) was
recovered then sequenced. Two-hybrid analysis was done using previ-
ously published plasmids [19]. For B42–Gβ (pLS3), the BamHI and
SalI fragment of pYEE160 [13] containing the Gβ coding region was
cloned into the BamHI site of pJG4-5 by blunt-end ligation at the SalI
site. LexA–Ste5(1–176), (1–214), (1–230) and (1–336) were made
by PCR amplifying the amino-terminal region of Ste5 using a 5′ primer
GCGGAATTCGGATCCATGATGGAAACTCCTAC, in combination
with 3′ primers CGCTAGGATCCTAAGAAGCATTCAAAAAG,
AGTGGATCCTTAAGTGGTGCCAAA, GCGATGGATCCTATTTAC-
ATTTGGTCAA, and AGTGGATCCTTAAATTCTTCTGTGCCCCAG,
respectively. The PCR products were digested with BamHI and
cloned into the BamHI site of pEG202 (pLS30, pLS8, pLS31 and
pLS11, respectively, for Ste5 and pLS9, pLS32, pLS12, pLS7 and
pLS10, respectively, for Ste5C180A). These PCR products were also
cloned into the BamHI site of plasmid ZM43 (URA3 CEN) under the
control of the GAL1 promoter (pLS33, pLS34, pLS35, pLS36, pLS38
and pLS39, respectively). Ste5–Myc9 was made by inserting nine
tandem c-Myc monoclonal antibody 9E10 epitopes before the Ste5
stop codon (S.K.M., L.Y.S., F. Farley, and E.A.E., unpublished). This
construct had wild-type function on a centromere plasmid, as assayed
by FUS1–LACZ, G1 arrest, mating, and activation of Fus3 kinase.
STE5–Myc9 was subcloned into YepLac180 and YepLac181 to
make STE5–Myc9 URA3 2µ (pSCEM21) and STE5–Myc9 LEU2 2µ.
(pLS40). STE5–Myc9 HIS3 2µ (pLS42) was made by inserting the
HIS3 gene on a BamHI fragment into the SmaI site of STE5–Myc9
URA3 2µ by blunt-end ligation. The URA3 marker was then disrupted
by digesting with NcoI and blunt-end religation. STE5C180A–Myc9
URA3 2µ (pSCEM22) was made by replacing the wild-type SphI–AflII
fragment in STE5–Myc9 URA3 2µ with the corresponding fragment
containing the C180A mutation. Plasmids ste5C180A–Myc9 LEU2
2µ (pLS41) and ste5C180A–Myc9 HIS3 2µ (pLS43) were con-
structed from STE5C180A–Myc9 URA3 2µ as described for Ste5.
STE5–Myc9 HIS3 CEN (pLS44) and ste5C180A–Myc9 HIS3 CEN
(pLS45) were made by subcloning the SphI–SacI fragment of
STE5–Myc9 HIS3 2µ and ste5C180A–Myc9 HIS3 2µ into
YCplac22. The ste5∆LIM mutation was made by PCR-amplifying the
region flanking amino acids 176 to 230 with oligo pairs
ATGACCATGATTACGCC and TCGGCGTACGCGTGAAGCATT-
CAAAAAGGATTTTT; AGCTTCACGCGTAGATACTAACAAAGCCG
and GAACAGATTGTATACTG. The PCR products were digested by
HindIII and MluI and MluI and SalI, respectively, and ligated at the
HindIII and SalI sites in STE5–Myc9 HIS3 2µ to yield
ste5∆LIM–Myc9 HIS3 2µ. (pLS46) which deletes residues 177–229
and changes lysine 230 to arginine and lysine 231 to valine. The
ste5(1–242)–Myc9 (pLS47) and ste5C180A(1–242)–Myc9
(pLS48) plasmids were made from STE5–Myc HIS3 2µ by releasing
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Table S1
Yeast strains used in this study.
Yeast strain Genotype Source 
EY492 MATa lys9 (L1543) J. Brill
AMR70 MATa URA3::lexAop-LacZ his3∆200 leu2-3,112, ade2, lys2-801 P. Bartel
W303a MATa FUS3 KSS1 ura3-1 leu2-3,112 trp1-1 his3-11,15 
ade2-1 can1-100 Gal+ R. Rothstein
Isogenic derivatives of W303a 
EY957 sst1∆ [12]
EY1118 sst1∆ his3∆200 lys2::FUS1-HIS3 [25]
EY1411 sst1∆ ste11∆::URA3 fus3-8::ADE2 E. Elion
EY1463 sst1∆ ste20∆::TRP1 [25]
EY1298 sst1∆ STE11-4 far1∆ lys2::FUS1-HIS3 his3∆200 [25]
EY1775 sst1∆ ste5∆::TRP1 [17]
EY1981 sst1∆ STE11-4 ste20∆::URA3 far1∆ lys2::FUS1-HIS3 his3∆200 [25]
EY2019 sst1∆ ste5∆::TRP1 far1∆ lys2::FUS1-HIS3 his3∆200 F. Farley
EY2022 sst1∆ STE11-4 ste20∆::TRP1 far1∆ lys2::FUS1-HIS3 his3∆200 [25]
EY2372 sst1∆ bem1∆::LEU2 ste5∆::TRP1 [25]
EY2565 sst1∆ STE11-4 far1∆ lys2::FUS1-HIS3 his3∆200 FAR1::URA3 V. Cherkasova
S36 sst1∆ ste5∆::TRP1 ste4∆::LEU2 (ste4∆ derivative of EY1775) This study
S37 sst1∆ STE11-4 ste5∆::TRP1 FAR1:: URA3 lys2::FUS1-HIS3 
his3∆200 (ste5∆ derivative of EY2565) This study
S74 sst1∆ STE11-4 ste5∆::TRP1 far1∆ lys2::FUS1-HIS3 his3∆200
(ste5∆ derivative of EY2565) This study
the NsiI–XhoI fragment with a NsiI–XhoI linker made by annealing
oligos TTCCAGAATTC and TCGAGAATTCTGGAATGCA. Plasmid
pYEE181 (pGAL–His6–HA–Ste4 URA3 CEN) was constructed by
inserting a His6–HA epitope tag into the amino terminus of Gβ. The
His6–HA tag was made by annealing 5′ oligo His6–HA1 (GATCTA-
TGGCACATCATCATCATCATCATTACCCAT) and 3′ oligo
His6–HA2 (GATCCAGCGTAGTCTGGGACGTCGTATGGGTAA-
TG), filling in the ends with Klenow, and then PCR-amplifying with 5′
oligo His6–HA1b (GCGCGAATTCAGATCTATGGCACATC) and 3′
oligo His6–HA1b (GCGCGTCGACGGATCCAGCGTAGTCT). This
PCR product was digested by BglII and BamHI and ligated into the
BamHI site of pL19. GST–STE5C180A (pLS29) was constructed by
digesting GST–STE5 (pYEE170) completely with SpeI, and partially
by KpnI, releasing the wild-type STE5 KpnI–SpeI fragment and replac-
ing it with the corresponding ste5C180A fragment. The
pGAL1–STE20 LEU2 CEN (ZM44Ste20) and pGAL1–STE50 LEU2
CEN (ZM44Ste50) plasmids will be described elsewhere. All PCR
amplification was done with Pfu DNA polymerase (Stratagene) and all
products were either sequenced or confirmed by examination of multi-
ple independent clones.
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Table S2
Plasmids used in this study.
Plasmid Description Source 
pYEE161 GAL1p–GST LEU2 2µ [18]
pYEE170 GAL1p–GST–STE5 LEU2 2µ [19]
pYEE166 GAL1p–GST–STE5 ∆143-313 LEU2 2µ This study
pLS29 GAL1p–GSTste5C180A LEU2 2µ This study
LexA–Ste11 ADH1p–LexA–STE11 HIS32µ [19]
LexA–Ste7 ADH1p–LexA–STE7 HIS32µ [19]
LexA–Fus3 ADH1p–LexA–FUS3 HIS32µ [19]
pLS30 ADH1p–LexA–STE(1–176) HIS32µ This study
pLS8 ADH1p–LexA–STE5(1–214) HIS32µ This study
pLS31 ADH1p–LexA–STE5(1–230) HIS32µ This study
pL11 ADH1p–LexA–STE5(1–336) HIS32µ This study
pLS9 ADH1p–LexA–ste5C180A(1–214) HIS32µ This study
pLS32 ADH1p–LexA–ste5C180A(1–230) HIS32µ This study
pLS12 ADH1p–LexA–ste5C180A(1–336) HIS32µ This study
pLS7 ADH1p–LexA–STE5(1–917) HIS32µ This study
pLS10 ADH1p–LexA–ste5C180A(1–336) HIS32µ This study
pYBS146 GAL1p–B42–STE5(24–917) TRP12µ [19]
pLS4 GAL1p–B42–ste5C180A(24–917)TRP1 2µ This study
pLS33 GAL1p–STE5(1–176) URA3 CEN This study
pLS34 GAL1p–STE5(1–214) URA3 CEN This study
pLS35 GAL1p–ste5C180A(1–214) URA3 CEN This study
pLS36 GAL1p–STE5(1–230) URA3 CEN This study
pLS37 GAL1p–ste5C180A(1–230) URA3 CEN This study
pLS38 GAL1p–STE5(1–336) URA3 CEN This study
pLS39 GAL1p–ste5C180A(1–336) URA3 CEN This study
pYBS138 STE5 URA3 CEN [18]
pEK1 ste5C180A URA3 CEN This study
pSCEM20 STE5 URA3 2µ This study
pKC20 STE5M URA3 2µ [19]
pLS16 ste5C180AM URA3 2µ This study
pLS5 STE5M URA3 CEN This study
pLS6 ste5C180AM URA3 CEN This study
pSCEM21 STE5–Myc9 URA3 2µ This study
pLS40 STE5–Myc9 LEU2 2µ This study
pLS42 STE5–Myc9 HIS32µ This study
pLS44 STE5–Myc9 HIS3 CEN This study
pSCEM22 ste5C180A–Myc9 URA3 2µ This study
pLS41 ste5C180A–Myc9 LEU2 2µ This study
pLS43 ste5C180A–Myc9 HIS3 2µ This study
pLS45 ste5C180A–Myc9 HIS3 CEN This study
pLS46 ste5C∆LIM–Myc9 HIS3 2µ This study
pLS47 STE5(1–242)–Myc9 HIS3 2µ This study
pLS48 ste5C180A(1–242)–Myc9 HIS3 2µ This study
pYEE181 GAL1p–His6–HA–STE4 URA3 CEN This study
pL19 GAL1p–STE4 URA3 CEN [37]
pYEE 116 GAL1p–STE4 HIS3 CEN [11]
ZM44Ste20 GAL1p–STE20 LEU2 CEN This study
ZM44Ste50 GAL1p–STE50 LEU2 CEN This study
pKC55 GAL1p–STE7M HIS3 CEN [19]
pNC245 GAL1p–STE11M TRP1 CEN [19]
pJB207 FUS1–LACZ LEU2 2µ [18]
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